ARCHIVES

New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB.

This article is from The Cancer Letter archive.

Vol. 30 No. 38 | October 8, 2004

Download PDF Visit The Full Archive

Related Articles

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

CCOPs Get $1 Million More, Payline Raised To 228 Plus Exceptions

May 29, 1987

NCI Advisory Group, Other Cancer Meetings for Oct., Nov., Future

September 29, 1989

In Brief: Tomasi To Resign As Roswell Park President; Committee To Study NIH Grant Review Issues

December 15, 1995

Tykerb And Trastuzumab Showed Increase In PFS For HER2+ Breast Cancer In Study

May 30, 2008

Sequestration: $1.71 Billion Cut to NIH Budget Will Reduce Number of RPGs

May 17, 2013